CIN No:- L24230PB2006PLC030341 GST No:- 02AAHCA5390H2ZT





Date 09 07 2022

Ref. No. ANG/22-23 /BSE-67

To

Department of Corporate Services **BSE Limited**P.J. Tower, Dalal Street

Mumbai -400001

Ref: Security Code 540694

Sub: Intimation of In-principle approval for issue and proposed allotment of Bonus Equity Shares.

Dear Sir/Madam,

Pursuant to regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, we hereby inform you that our Company has received the In-Principle Approval vide letter no. DCS/AMAL/VK/BN-IP/2417/2022-23 dated July, 08, 2022 in regards to the issue and proposed allotment of Bonus Equity Shares in the ratio of 1:4 i.e. 1 (one) new equity shares for every 4 (four) existing equity shares.

Please find enclosed herewith the copy of In-principle Approval of the BSE Ltd.

Thanking You,

For ANG Lifesciences India Limited

Renu Kaur

Company secretary & Compliance Officer

M.No. A62402

BSE Limited Registered Office: Floor 25, P J Towers, Dalal Street, Mumbai – 400 001, India T:+91 22 2272 8045 / 8055 F:+91 22 2272 3457 www.bseindia.com

Corporate Identity Number: L67120MH2005PLC155188



DCS/AMAL/VK/BN-IP/2417/2022-23

"E-Letter"

July 08, 2022

The Company Secretary, **ANG Lifesciences India Ltd**SCO 113, Darbara Complex,

1st Floor, District Shopping Centre B Block,
Ranjit Avenue, Amritsar, Punjab, 143001

Dear Sir/Madam

Re: Application of proposed Bonus Equity Shares under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

We acknowledge receipt of your application regarding in-principle approval for issue and allotment of proposed Bonus equity shares to the shareholders in terms of Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. In this regard, the Exchange is pleased to grant in-principle approval for issue and proposed allotment of not exceeding 25,91,657 Bonus equity shares of Rs. 10/- each in the ratio of 1 (One) new equity share for every 4 (Four) existing equity shares held in the Company subject to the company fulfilling the following conditions:

- Submission of listing application form for the new securities to be allotted and documents as per Format available on the website of BSE Ltd. under following link http://www.bseindia.com/static/about/downloads.aspx
- 2. Payment of Additional listing fees on the enhanced capital, if applicable.
- 3. Receipt of statutory and other approvals and compliance with guidelines issued by the statutory authorities including SEBI, RBI, MCA etc.
- 4. Compliance with any change in the guidelines, regulations directions of the Exchange or any statutory authorities, documentary requirements from time to time.
- 5. Compliance with all conditions of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as on date of listing.
- 6. Compliance with the Companies Act, 2013 and other applicable laws.

In addition to above, the company should note that as per Schedule XIX – Para (2) of ICDR Regulations and as specified in SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/94 dated August 19, 2019, "the issuer or the issuing company, as the case may be, shall, make an application for listing, within twenty days from the date of allotment, to one or more recognized stock exchange(s)" along with the documents specified by stock exchange(s) from time to time. Any Non-compliance with the above requirement will attract, the fine as mentioned in SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/94 dated August 19, 2019.

The Exchange reserves its right to withdraw its in-principle approval at any later stage if the information submitted to the Exchange is found to be incomplete/incorrect/misleading/false/or for any contravention of Rules, Bye-laws and Regulations of the Exchange.

This approval is valid up to the time specified in 295(1) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and any non-compliance with the said requirement will attract, the fine as mentioned in SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/94 dated August 19, 2019.

Kindly note that the Exchange will issue approval for listing subject to the compliances as stated above.

Yours faithfully, Sd/-Sabah Vaze Senior Manager



